Category News

Quarter

InfuSystem to Announce Third Quarter 2025 Financial Results on November 4, 2025

InfuSystem to Report Q3 2025 Results on November 4 Rochester Hills, Mich., October 29, 2025 — InfuSystem Holdings, Inc. (NYSE American: INFU), a national healthcare service provider known for supporting outpatient care and durable medical equipment (DME) manufacturers, announced that…

Read MoreInfuSystem to Announce Third Quarter 2025 Financial Results on November 4, 2025

Hyundai Translead to Oversee Distribution of XCIENT Fuel Cell Trucks Across North America

Hyundai Translead to Become Official Distributor of Hyundai’s XCIENT Fuel Cell Trucks in North America In a strategic move that underscores Hyundai’s accelerating commitment to zero-emission commercial mobility, Hyundai Translead has been appointed as the official distributor of Hyundai Motor…

Read MoreHyundai Translead to Oversee Distribution of XCIENT Fuel Cell Trucks Across North America

Early Use of Delve Bio’s Metagenomic Test Cuts Conventional Testing and Hospital Stay in Meningitis/Encephalitis Patients

a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at IDWeek 2025™ in Atlanta, Ga., by researchers from Columbia University Irving Medical Center show metagenomic sequencing that detects both RNA and DNA pathogens, available through Delve…

Read MoreEarly Use of Delve Bio’s Metagenomic Test Cuts Conventional Testing and Hospital Stay in Meningitis/Encephalitis Patients

Iambic Reports Phase 1/1B Data for IAM1363 Showing Monotherapy Activity in HER2-Altered Patients at ESMO 2025

Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced clinical data for IAM1363, a brain-penetrant HER2 small-molecule tyrosine kinase inhibitor (TKI), which showed anti-tumor activity in heavily pretreated…

Read MoreIambic Reports Phase 1/1B Data for IAM1363 Showing Monotherapy Activity in HER2-Altered Patients at ESMO 2025